Cogent Biosciences (COGT) Common Equity (2017 - 2026)

Cogent Biosciences' Common Equity history runs 10 years deep, the most recent figure standing at $607.7 million for Q1 2026.

• In Q1 2026, Common Equity rose 177.49% year-over-year to $607.7 million; the TTM figure through Mar 2026 stood at $607.7 million (up 177.49% YoY), while the FY2025 annual figure was $636.4 million, up 148.31% from the prior year.
• Common Equity was $607.7 million for Q1 2026 at Cogent Biosciences, down from $636.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $636.4 million in Q4 2025 to a low of $155.0 million in Q2 2025.
• Historically, Common Equity has averaged $321.9 million across 5 years, with a median of $302.5 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Common Equity plunged 58.46% in 2025, then soared 177.49% in 2026.
• A 5-year view of Common Equity shows it stood at $255.7 million in 2022, then climbed by 0.81% to $257.8 million in 2023, then dropped by 0.59% to $256.3 million in 2024, then soared by 148.31% to $636.4 million in 2025, then dropped by 4.51% to $607.7 million in 2026.
• The last three Common Equity figures came in at $607.7 million (Q1 2026), $636.4 million (Q4 2025), and $302.5 million (Q3 2025), per Business Quant data.